van Dijk Laura K, Boerman Otto C, Kaanders Johannes H A M, Bussink Johan
a Department of Radiation Oncology , Radboud University Medical Center , Nijmegen , The Netherlands.
b Department of Radiology and Nuclear Medicine , Radboud University Medical Center , Nijmegen , The Netherlands.
Acta Oncol. 2015;54(9):1263-7. doi: 10.3109/0284186X.2015.1063778. Epub 2015 Aug 6.
Molecular imaging of specific biomarkers can have prognostic, predictive or monitoring value in head and neck squamous cell carcinoma (HNSCC). The epidermal growth factor receptor (EGFR) is involved in various radiation resistance mechanisms as it steers the pathways related to DNA damage repair, proliferation, hypoxia and apoptosis. Radiolabeled labeled F(ab')2 fragments of the EGFR antibody cetuximab can be applied for non-invasive imaging of this receptor. Preclinical studies have shown that radioresistant tumors had a higher tracer uptake after irradiation, probably due to upregulation of membranous EGFR, thereby increasing target availability possibly as a compensation mechanism. Tumors with increased EGFR availability were also more responsive to the EGFR inhibitor cetuximab. Potentially, radionuclide imaging of the EGFR can be applied for monitoring treatment regimens in clinical practice.
特定生物标志物的分子成像在头颈部鳞状细胞癌（HNSCC）中具有预后、预测或监测价值。表皮生长因子受体（EGFR）参与多种辐射抵抗机制，因为它操控与DNA损伤修复、增殖、缺氧和凋亡相关的信号通路。表皮生长因子受体抗体西妥昔单抗的放射性标记F(ab')2片段可用于该受体的无创成像。临床前研究表明，放射抗性肿瘤在照射后示踪剂摄取更高，这可能是由于膜性EGFR上调，从而增加了靶点可及性，这可能是一种补偿机制。EGFR可及性增加的肿瘤对EGFR抑制剂西妥昔单抗也更敏感。在临床实践中，EGFR的放射性核素成像有可能用于监测治疗方案。
